Growth and growth hormone secretion in children following treatment of brain tumours with radiotherapy.
We have studied the growth of 144 children after treatment of brain tumours distant from the hypothalamo-pituitary axis. All had cranial irradiation and 87 spinal irradiation. In 56 patients observed without intervention for 3 years, height SDS in the cranial (CR) group (n = 20) declined from 0.02 to -0.44 and in the craniospinal (CS) group (n = 36) from -0.28 to -1.11. Failure of spinal growth had a marked effect in the CS group. The onset of puberty was slightly but not significantly advanced; median ages at onset of puberty were 10.3 years in girls and 12.1 years in boys. Of the total group 86.4% had clinical and biochemical evidence of growth hormone insufficiency. Fifty-two children, 33 (28 CS; 5 CR) of whom were prepubertal, received biosynthetic human growth hormone, in a dose of 15 mU/m2/week by daily injection for a period of one year. Height velocity SDS increased significantly in both groups from -2.74 to +1.90 (CS) and from -1.0 to +4.26 (CR). Spinal response to GH treatment was restricted in the craniospinal group.
Darendeliler
F
F
Endocrine Unit, Middlesex Hospital, London, U.K.
Livesey
E A
EA
Hindmarsh
P C
PC
Brook
C G
CG
D001921:Brain / Q000528:radiation effects; D001932:Brain Neoplasms / Q000532:radiotherapy*; D002648:Child; D005260:Female; D006128:Growth / Q000528:radiation effects*; D006130:Growth Disorders / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011627:Puberty / Q000528:radiation effects; D011879:Radiotherapy Dosage; D013131:Spine / Q000528:radiation effects
D013006:Growth Hormone